Table 3.

Factors associated with partial or complete renal remission at the end of follow-up

FactorRenal remission at end of follow-upP
+-
(n = 12)(n = 8)
Median age, years (range)24.5 (18 to 35)24 (17 to 37)NS
Black ethnicity, n (%)1 (8)6 (75)0.004
Class III/IV LN, n (%)10 (83)5 (62)NS
RPGN, n (%)03 (37)0,05
Median Pu, g/day (range)5.5 (0.5 to 25)4.5 (3 to 9)NS
Median serum Alb, g/L (range)24.5 (19 to 40)19.5 (11 to 28)0.08
Median eGFR, ml/min/1.73 m2 (range)72 (9 to 150)62 (0 to 133)NS
Median C3, % normal (range)44 (15 to 121)39 (30 to 130)NS
Baseline positive anti-dsDNA Ab, n (%)11 (92)6/7 (86)NS
Negative anti-dsDNA Ab at end of follow-up (among positive at baseline), n (%)5 (45%)2 (33%)NS
IV Cs, n (%)8 (75%)4 (50%)NS
CYP, n (%)1 (8%)2 (25%)NS
MMF, n (%)1 (8%)2 (25%)NS
B cell depletion at M111/111/6<0.001
Overall B cell depletion11/113/60.03
  • P values are by Fisher's exact test for categorical data and by Wilcoxon rank sum test with continuity correction for continuous data. NS, not significant; LN, lupus nephritis; RPGN, rapidly progressive glomerulonephritis; Pu, baseline proteinuria; serum Alb, baseline albuminemia; eGFR, baseline estimated glomerular filtration rate; C3: baseline C3 complement; anti-dsDNA Ab, anti-double stranded DNA antibody; IV Cs, intravenous corticosteroids associated with rituximab; CYP, cyclophosphamide associated with rituximab; MMF, mycophenolate mofetil associated wit RTX; M1, 1 mo after rituximab initiation.